|
1
|
Balkwill F and Coussens LM: Cancer: An
inflammatory link. Nature. 431:405–406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang N, Reeves KJ, Brown HK, Fowles ACM,
Docherty FE, Ottewell PD, Croucher PI, Holen I and Eaton CL: The
frequency of osteolytic bone metastasis is determined by conditions
of the soil, not the number of seeds; evidence from in vivo models
of breast and prostate cancer. J Exp Clin Cancer Res. 34:1242015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Larkin JR, Dickens AM, Claridge TD,
Bristow C, Andreou K, Anthony DC and Sibson NR: Early diagnosis of
brain metastases using a biofluids-metabolomics approach in mice.
Theranostics. 6:2161–2169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun DW, Zhang HD, Mao L, Mao CF, Chen W,
Cui M, Ma R, Cao HX, Jing CW, Wang Z, et al: Luteolin inhibits
breast cancer development and progression in vitro and in vivo by
suppressing notch signaling and regulating MiRNAs. Cell Physiol
Biochem. 37:1693–1711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kreutzman A, Juvonen V, Kairisto V, Ekblom
M, Stenke L, Seggewiss R, Porkka K and Mustjoki S: Mono/oligoclonal
T and NK cells are common in chronic myeloid leukemia patients at
diagnosis and expand during dasatinib therapy. Blood. 116:772–782.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mustjoki S, Auvinen K, Kreutzman A,
Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM,
Hautaniemi S, Bouchet S, Molimard M, et al: Rapid mobilization of
cytotoxic lymphocytes induced by dasatinib therapy. Leukemia.
27:914–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gridling M, Ficarro SB, Breitwieser FP,
Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga
G, Bennett KL and Rix U: Identification of kinase inhibitor targets
in the lung cancer microenvironment by chemical and
phosphoproteomics. Mol Cancer Ther. 13:2751–2762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lowe DB, Bose A, Taylor JL, Tawbi H, Lin
Y, Kirkwood JM and Storkus WJ: Dasatinib promotes the expansion of
a therapeutically superior T-cell repertoire in response to
dendritic cell vaccination against melanoma. Oncoimmunology.
3:e275892014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iriyama N, Fujisawa S, Yoshida C, Wakita
H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi
K, et al: Early cytotoxic lymphocyte expansion contributes to a
deep molecular response to dasatinib in patients with newly
diagnosed chronic myeloid leukemia in the chronic phase: Results of
the D-first study. Am J Hematol. 90:819–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimura Y, Horiike S, Tsutsumi Y, Hatsuse
M, Okano A, Fuchida S, Kobayashi T, Matsumoto Y, Kuroda J,
Kawata-Iida E, et al: The longitudinal analysis of large granular
lymphocytosis in patients with Philadelphia chromosome-positive
leukemia treated with dasatinib. Int J Hematol. 102:426–433. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christiansson L, Soderlund S, Mangsbo S,
Hjorth-Hansen H, Hoglund M, Markevarn B, Richter J, Stenke L,
Mustjoki S, Loskog A and Olsson-Strömberg U: The tyrosine kinase
inhibitors imatinib and dasatinib reduce myeloid suppressor cells
and release effector lymphocyte responses. Mol Cancer Ther.
14:1181–1191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim DH, Kamel-Reid S, Chang H, Sutherland
R, Jung CW, Kim HJ, Lee JJ and Lipton JH: Natural killer or natural
killer/T cell lineage large granular lymphocytosis associated with
dasatinib therapy for Philadelphia chromosome positive leukemia.
Haematologica. 94:135–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Finn RS, Bengala C, Ibrahim N, Roche H,
Sparano J, Strauss LC, Fairchild J, Sy O and Goldstein LJ:
Dasatinib as a single agent in triple-negative breast cancer:
Results of an open-label phase 2 study. Clin Cancer Res.
17:6905–6913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fornier MN, Morris PG, Abbruzzi A,
D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S,
Seidman AD, et al: A phase I study of dasatinib and weekly
paclitaxel for metastatic breast cancer. Ann Oncol. 22:2575–2581.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Somlo G, Atzori F, Strauss LC, Geese WJ,
Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT and Cortes J:
Dasatinib plus capecitabine for advanced breast cancer: Safety and
efficacy in phase I study CA180004. Clin Cancer Res. 19:1884–1893.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Algazi AP, Weber JS, Andrews SC, Urbas P,
Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T
and Daud AI: Phase I clinical trial of the Src inhibitor dasatinib
with dacarbazine in metastatic melanoma. Br J Cancer. 106:85–91.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolfl M, Schwinn S, Yoo YE, Ress ML, Braun
M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, et al:
Src-kinase inhibitors sensitize human cells of myeloid origin to
Toll-like-receptor-induced interleukin 12 synthesis. Blood.
122:1203–1213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nerreter T, Köchel C, Jesper D,
Eichelbrönner I, Putz E, Einsele H and Seggewiss-Bernhardt R:
Dasatinib enhances migration of monocyte-derived dendritic cells by
reducing phosphorylation of inhibitory immune receptors Siglec-9
and Siglec-3. Exp Hematol. 42(773–782): e1–3. 2014.
|
|
19
|
Yang Y, Liu C, Peng W, Lizee G, Overwijk
WW, Liu Y, Woodman SE and Hwu P: Antitumor T-cell responses
contribute to the effects of dasatinib on c-KIT mutant murine
mastocytoma and are potentiated by anti-OX40. Blood. 120:4533–4543.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee F, Jure-Kunkel MN and Salvati ME:
Synergistic activity of ixabepilone plus other anticancer agents:
Preclinical and clinical evidence. Ther Adv Med Oncol. 3:11–25.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Somlo G, Atzori F, Strauss LC, Geese WJ,
Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT and Cortes J:
Dasatinib plus capecitabine for advanced breast cancer: Safety and
efficacy in phase I study CA180004. Clin Cancer Res. 19:1884–93.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Zhao Y, Chu X, Lu Y, Wang S and Yi
Q: Dectin-1-activated dendritic cells: A potent Th9 cell inducer
for tumor immunotherapy. Oncoimmunology. 5:e12385582016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schietinger A and Greenberg PD: Tolerance
and exhaustion: Defining mechanisms of T cell dysfunction. Trends
Immunol. 35:51–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Makkouk A and Weiner GJ: Cancer
immunotherapy and breaking immune tolerance: New approaches to an
old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garcia AJ, Ruscetti M, Arenzana TL, Tran
LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale
ST and Wu H: Pten null prostate epithelium promotes localized
myeloid-derived suppressor cell expansion and immune suppression
during tumor initiation and progression. Mol Cell Biol.
34:2017–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keskinov AA and Shurin MR: Myeloid
regulatory cells in tumor spreading and metastasis. Immunobiology.
220:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: A
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Almand B, Resser JR, Lindman B, Nadaf S,
Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical
significance of defective dendritic cell differentiation in cancer.
Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
|
|
30
|
Blake S, Hughes TP, Mayrhofer G and Lyons
AB: The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits
function of normal human T-lymphocytes in vitro. Clin Immunol.
127:330–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blake SJ, Bruce LA, Fraser CK, Hayball JD
and Hughes TP: Dasatinib suppresses in vitro natural killer cell
cytotoxicity. Blood. 111:4415–4416. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schade AE, Schieven GL, Townsend R,
Jankowska AM, Susulic V, Zhang R, Szpurka H and Maciejewski JP:
Dasatinib, a small-molecule protein tyrosine kinase inhibitor,
inhibits T-cell activation and proliferation. Blood. 111:1366–1377.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weichsel R, Dix C, Wooldridge L, Clement
M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price
DA, et al: Profound inhibition of antigen-specific T-cell effector
functions by dasatinib. Clin Cancer Res. 14:2484–2491. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Valent JN and Schiffer CA: Prevalence of
large granular lymphocytosis in patients with chronic myelogenous
leukemia (CML) treated with dasatinib. Leuk Res. 35:e1–e3. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang L, DeBusk LM, Fukuda K, Fingleton B,
Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP and Lin PC:
Expansion of myeloid immune suppressor Gr+CD11b+ cells in
tumor-bearing host directly promotes tumor angiogenesis. Cancer
Cell. 6:409–421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heine A, Held SA, Bringmann A, Holderried
TA and Brossart P: Immunomodulatory effects of anti-angiogenic
drugs. Leukemia. 25:899–905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weisberg E, Manley PW, Cowan-Jacob SW,
Hochhaus A and Griffin JD: Second generation inhibitors of BCR-ABL
for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer. 7:345–356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Finke JH, Rini B, Ireland J, Rayman P,
Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and
Bukowski R: Sunitinib reverses type-1 immune suppression and
decreases T-regulatory cells in renal cell carcinoma patients. Clin
Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ko JS, Zea AH, Rini BI, Ireland JL, Elson
P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al:
Sunitinib mediates reversal of myeloid-derived suppressor cell
accumulation in renal cell carcinoma patients. Clin Cancer Res.
15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck
M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH: The novel
role of tyrosine kinase inhibitor in the reversal of immune
suppression and modulation of tumor microenvironment for
immune-based cancer therapies. Cancer Res. 69:2514–2522. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bose A, Taylor JL, Alber S, Watkins SC,
Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH and Storkus WJ:
Sunitinib facilitates the activation and recruitment of therapeutic
anti-tumor immunity in concert with specific vaccination. Int J
Cancer. 129:2158–2170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bose A, Lowe DB, Rao A and Storkus WJ:
Combined vaccine+axitinib therapy yields superior antitumor
efficacy in a murine melanoma model. Melanoma Res. 22:236–243.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yuan H, Cai P, Li Q, Wang W, Sun Y, Xu Q
and Gu Y: Axitinib augments antitumor activity in renal cell
carcinoma via STAT3-dependent reversal of myeloid-derived
suppressor cell accumulation. Biomed Pharmacother. 68:751–756.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bonecchi R, Bianchi G, Bordignon PP,
D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA,
Mantovani A and Sinigaglia F: Differential expression of chemokine
receptors and chemotactic responsiveness of type 1 T helper cells
(Th1s) and Th2s. J Exp Med. 187:129–134. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Basset L, Chevalier S, Danger Y, Arshad
MI, Piquet-Pellorce C, Gascan H and Samson M: Interleukin-27 and
IFNg regulate the expression of CXCL9, CXCL10, and CXCL11 in
hepatitis. J Mol Med (Berl). 93:1355–1367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bol KF, Figdor CG, Aarntzen EH, Welzen ME,
van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer
AJ, Pots JM, et al: Intranodal vaccination with mRNA-optimized
dendritic cells in metastatic melanoma patients. OncoImmunology.
4:e10191972015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Carreno BM, Magrini V, Becker-Hapak M,
Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH,
Mardis ER and Linette GP: Cancer immunotherapy. A dendritic cell
vaccine increases the breadth and diversity of melanoma
neoantigen-specific T cells. Science. 348:803–808. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pizzurro GA and Barrio MM: Dendritic
cell-based vaccine efficacy: Aiming for hot spots. Front Immunol.
6:912015. View Article : Google Scholar : PubMed/NCBI
|
